Albert Bourla
CEO Bourla's operational excellence and leadership are praised, but his acquisition choices and R&D management have been criticized, impacting Pfizer's growth.
Despite success with Pfizer's Covid vaccine, Bourla's focus on reputation and slow reaction to negative trends have hindered his ability to reignite growth.
Sources say Bourla's aggressive goal-setting is both a strength and a weakness, with Pfizer's culture favoring internally-developed leaders, leaving questions about future leadership.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.